scholarly journals Cardiac Tamponade during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity

2021 ◽  
Author(s):  
Daisuke Miyahara ◽  
Yuichi Moriyama ◽  
Yuka Yamazaki ◽  
Hironobu Tanii ◽  
Yoshifumi Okano ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiac Tamponade ◽  
Antibody Positivity

Pericarditis and Cardiac Tamponade in Juvenile Rheumatoid Arthritis

PEDIATRICS ◽  
1981 ◽  
Vol 68 (3) ◽  
pp. 369-373 ◽  
Author(s):  
Carolyn L. Yancey ◽  
Robert A. Doughty ◽  
Barbara A. Cohlan ◽  
Balu H. Athreya
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiac Tamponade ◽  
Juvenile Rheumatoid Arthritis ◽  
Sinus Tachycardia ◽  
Rare Complication ◽  
Shortness Of Breath ◽  
Significant Morbidity ◽  
T Wave ◽  
Inflammatory Drugs

Cardiac tamponade is a rare complication of juvenile rheumatoid arthritis. Three cases seen in the last two years at the Children's Hospital of Philadelphia are reported and compared to four previously reported cases. All three children had systemic-type juvenile rheumatoid arthritis with tachypnea, shortness of breath, and chest pain. Cardiac signs in these children included decreased heart sounds, pericardial friction rub, jugular venous distention, and pulsus paradoxus greater than 12 mm Hg. Roentgenograms of the chest showed cardiomegaly with bilateral pleural effusions. Electrocardiograms showed sinus tachycardia and nonspecific ST-T wave changes. Echocardiograms demonstrated pericardial effusions in all subjects and poor ventricular movements in one child. All three children were treated with short-acting anti-inflammatory drugs and/or prednisone. Pericardiocentesis was performed in two cases. There was no significant morbidity after a mean follow-up of two years.

scholarly journals Cardiac tamponade in rheumatoid arthritis.

1984 ◽  
Vol 60 (705) ◽  
pp. 474-475 ◽  
Author(s):  
P. Sanchez-Garcia ◽  
M. Cordero-Sanchez ◽  
P. Pavon-Osuna ◽  
A. Arribas-Jimenez ◽  
J. del Pino-Montes ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiac Tamponade

Successful treatment of refractory cardiac tamponade due to rheumatoid arthritis using pericardial drainage

2009 ◽  
Vol 30 (8) ◽  
pp. 1103-1106
Author(s):  
Hiroko Imadachi ◽  
Shunsuke Imadachi ◽  
Tomohiro Koga ◽  
Taichiro Miyashita ◽  
Yasumori Izumi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiac Tamponade ◽  
Successful Treatment ◽  
Pericardial Drainage

TCONS_00483150 as a novel diagnostic biomarker of systemic lupus erythematosus

Epigenomics ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 973-988
Author(s):  
Gangqiang Guo ◽  
Aqiong Chen ◽  
Lele Ye ◽  
Huijing Wang ◽  
Zhiyuan Chen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Noncoding Rnas ◽  
Differentially Expressed ◽  
Healthy Controls ◽  
Diagnostic Biomarker ◽  
Systemic Lupus ◽  
Functional Roles ◽  
Antibody Positivity

Aim: We aimed to identify differentially expressed Long noncoding RNAs (lncRNAs) and explore their functional roles in systemic lupus erythematosus (SLE). Materials & methods: We identified dysregulated lncRNAs and investigated their prognostic values and potential functions using MiRTarget2, catRAPID omics and Bedtools/blast/Pearson analyses. Results: Among the 143 differentially expressed lncRNAs, TCONS_00483150 could be used to distinguish patients with SLE from healthy controls and those with rheumatoid arthritis and patients with active/stable SLE from healthy controls. TCONS_00483150 was significantly correlated with anti-Rib-P antibody positivity and low C3 levels; TCONS_00483150 dysregulation might contribute to the metabolism of RNA and proteins in SLE patients. Conclusion: Overall, our findings offer a transcriptome-wide overview of aberrantly expressed lncRNAs in patients with SLE and highlight TCONS_00483150 as a potential novel diagnostic biomarker.

scholarly journals Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

2014 ◽  
Vol 74 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Paul Emery ◽  
Gerd R Burmester ◽  
Vivian P Bykerk ◽  
Bernard G Combe ◽  
Daniel E Furst ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Early Rheumatoid Arthritis ◽  
Safety Profile ◽  
Treatment Withdrawal ◽  
Sustained Remission ◽  
Double Blind ◽  
Antibody Positivity ◽  
Registration Number ◽  
Maintenance Of Remission

ObjectivesTo evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis (RA), and maintenance of remission following the rapid withdrawal of all RA treatment.MethodsIn the Assessing Very Early Rheumatoid arthritis Treatment phase 3b trial, patients with early active RA were randomised to double-blind, weekly, subcutaneous abatacept 125 mg plus MTX, abatacept 125 mg monotherapy, or MTX for 12 months. Patients with low disease activity (Disease Activity Score (DAS)28 (C reactive protein (CRP)) <3.2) at month 12 entered a 12-month period of withdrawal of all RA therapy. The coprimary endpoints were the proportion of patients with DAS28 (CRP) <2.6 at month 12 and both months 12 and 18, for abatacept plus MTX versus MTX.ResultsPatients had <2 years of RA symptoms, DAS28 (CRP) ≥3.2, anticitrullinated peptide-2 antibody positivity and 95.2% were rheumatoid factor positive. For abatacept plus MTX versus MTX, DAS28 (CRP) <2.6 was achieved in 60.9% versus 45.2% (p=0.010) at 12 months, and following treatment withdrawal, in 14.8% versus 7.8% (p=0.045) at both 12 and 18 months. DAS28 (CRP) <2.6 was achieved for abatacept monotherapy in 42.5% (month 12) and 12.4% (both months 12 and 18). Both abatacept arms had a safety profile comparable with MTX alone.ConclusionsAbatacept plus MTX demonstrated robust efficacy compared with MTX alone in early RA, with a good safety profile. The achievement of sustained remission following withdrawal of all RA therapy suggests an effect of abatacept's mechanism on autoimmune processes.Trial registration numberNCT01142726.

scholarly journals Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid Arthritis

2015 ◽  
Vol 43 (2) ◽  
pp. 273-281 ◽  
Author(s):  
Gregory J. Challener ◽  
Jonathan D. Jones ◽  
Adam J. Pelzek ◽  
B. JoNell Hamilton ◽  
Gilles Boire ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Medical Center ◽  
Cross Reactivity ◽  
University Hospital ◽  
Variable Response ◽  
Antibody Positivity ◽  
Dartmouth Hitchcock Medical ◽  
Antibody Levels ◽  
Citrullinated Peptide

Objective.The presence of anticitrullinated protein antibodies (ACPA) in rheumatoid arthritis (RA) indicates a breach in immune tolerance. Recent studies indicate that this breach extends to homocitrullination of lysines with the formation of anti-carbamylated protein (anti-CarP) antibodies. We analyzed the clinical and serologic relationships of anti-CarP in 2 RA cohorts.Methods.Circulating levels of immunoglobulin G anti-CarP antibodies were determined by ELISA in established (Dartmouth-Hitchcock Medical Center) and early (Sherbrooke University Hospital Center) cohorts and evaluated for anticyclic citrullinated peptide antibodies (anti-CCP), specific ACPA, and rheumatoid factor (RF) levels using the Student t test and correlation analysis.Results.We identified elevated anti-CarP antibodies titers in 47.0% of seropositive patients (Dartmouth, n = 164), with relationships to anti-CCP (p < 0.0001) and IgM-RF (p = 0.001). Similarly, 38.2% of seropositive patients from the Sherbrooke cohort (n = 171) had elevated anti-CarP antibodies; titers correlated to anti-CCP (p = 0.01) but not IgM-RF (p = 0.09). A strong correlation with anti-Sa was observed: 47.9% anti-Sa+ patients were anti-CarP antibodies+ versus only 25.4% anti-Sa− in the Sherbrooke cohort (p = 0.0002), and 62.6% anti-Sa+ patients versus 26.9% anti-Sa− were anti-CarP antibodies+ in Dartmouth (p < 0.0001). We found a more variable response for reactivity to citrullinated fibrinogen or to citrullinated peptides from fibrinogen and α enolase.Conclusion.In 2 North American RA cohorts, we observed a high prevalence of anti-CarP antibody positivity. We also describe a surprising and unexpected association of anti-CarP with anti-Sa antibodies that could not be explained by cross-reactivity. Further, considerable heterogeneity exists between anti-CarP reactivity and other citrullinated peptide reactivity, raising the question of how the pathogenesis of antibody responses for carbamylated proteins and citrullinated proteins may be linked in vivo.

Sign in / Sign up

Export Citation Format

Share Document